Tandem Diabetes Stock Price, News & Analysis

Tandem Diabetes Care and Dexcom have announced that the t:slim X2 insulin pump with Dexcom G7 CGM compatibility has been authorized for sale by Health Canada. This integration makes it the only Automated Insulin Delivery (AID) system in Canada compatible with both Dexcom G7 and G6 CGM technologies. The updated software is expected to be commercially available this fall, with existing users receiving a free remote update.

Key features of the integration include:

• Dexcom G7's smaller, all-in-one sensor and transmitter
• 30-minute sensor warmup time
• 12-hour grace period for sensor replacement
• Increased connectivity with digital health apps

The t:slim X2 pump with Control-IQ technology is rated as the #1 AID system in Canada, offering customizable profiles and various infusion set options.

Tandem Diabetes Care (NASDAQ: TNDM) will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market closes. The company will hold a conference call and webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on the same day to discuss the financial and operating results. The live webcast will be available on Tandem Diabetes Care's Investor Center website. An archived version of the webcast will be accessible for 30 days post-event.

Tandem Diabetes Care (NASDAQ: TNDM), a leader in insulin delivery and diabetes technology, has appointed Jean-Claude 'JC' Kyrillos as the new Executive Vice President and Chief Operating Officer, effective June 21, 2024. Kyrillos brings over 20 years of global executive leadership experience in medical devices, digital health, and healthcare management.

Kyrillos previously held key roles at Envista Holdings, Qualcomm Life, Becton Dickinson, and ResMed. He has also served as an independent board director at the San Diego Blood Bank. Tandem's CEO, John Sheridan, highlighted Kyrillos' extensive technical, operational, and leadership skills.

Kyrillos expressed enthusiasm for joining Tandem, focusing on expanding global operations and delivering profitable growth while advancing their mission to improve lives through innovative insulin delivery technologies.

Tandem Diabetes Care (NASDAQ: TNDM) is set to present early user insights on its new Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions from June 21-24 in Orlando, Florida.

The Product Theater session, scheduled for June 22, will feature presentations by key medical experts on the benefits of Tandem Mobi, the world's smallest durable Automated Insulin Delivery (AID) system, and its Control-IQ algorithm. The presenters will discuss the system's unique wearability and potential to improve patient outcomes.

Additional poster presentations will cover various studies on the t:slim X2 insulin pump with Control-IQ Technology and the Tandem t:connect mobile application.

Tandem Diabetes Care will also exhibit at Booth #1621, showcasing the Tandem Mobi and t:slim X2 systems, both compatible with multiple Continuous Glucose Monitors (CGMs).

Tandem Diabetes Care announced the compatibility of its Tandem Mobi insulin pump with both Dexcom G7 and G6 CGM systems.

This integration enhances user flexibility, allowing choice in diabetes management. Tandem Mobi, the smallest automated insulin delivery system, launched in the U.S. earlier in 2023, offers greater discretion and comfort.

Users will receive free software updates for this feature via email. New pumps will ship with the updated software pre-loaded.

This move strengthens Tandem's partnership with Dexcom and builds on their decade-long collaboration in providing innovative diabetes solutions.

Tandem Diabetes Care (NASDAQ: TNDM) will present a company update at the Jefferies Global Healthcare Conference on June 6, 2024, at 8:00 am Eastern Time (5:00 am Pacific Time).

The update will be webcast live, with an archive available for 30 days on the company’s Investor Center website.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported a 13% increase in worldwide GAAP sales to $191.7 million and a 12% increase in non-GAAP sales to $192.8 million for the first quarter of 2024. The company launched Tandem Mobi with Dexcom G6 CGM sensor integration and t:slim X2 with Abbott Freestyle Libre 2 Plus CGM sensor integration in the US, among other initiatives. The increase in pump shipments and financial results showcased positive growth. However, the company reported a net loss for the quarter.

Tandem Diabetes Care, Inc. (TNDM) will present at investor conferences on May 15 and May 29, 2024, providing company updates. The presentations will be webcast live and archived for 30 days.